By Colin Kellaher

Bausch Health Cos. (BHC, BHC.T) on Wednesday said the U.S. Food and Drug Administration accepted a new-drug application for its Ortho Dermatologics unit's IDP-123 lotion for acne vulgaris, the most common skin problem in the U.S.

The Laval, Quebec, maker of pharmaceutical products said IDP-123, if approved, would be the first tazarotene acne treatment available in a lotion form.

Bausch said the FDA has set a target action date of Dec. 22 for the NDA.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

August 07, 2019 08:08 ET (12:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bausch Health Companies Charts.
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bausch Health Companies Charts.